secwatch.observer — SEC 8-K summary
======================================

Issuer:     Natera, Inc. (NTRA)
CIK:        0001604821
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001104659-26-020482
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Natera Q4 2025 revenue $665.5M (+39.8% YoY); guides FY26 revenue $2.62-2.70B
----------------------------------------------------------------------------

- Revenue $665.5M Q4 2025 vs $476.1M Q4 2024 (+39.8%); FY2025 revenue $2,306.1M (+35.9%).
- Gross margin 66.9% Q4 2025 vs 62.9% Q4 2024; FY2025 gross margin 64.7%.
- Oncology test volumes up 54.7% YoY in Q4 (233,300 tests) and 51.6% for FY2025.
- Full-year positive cash inflow of $107.6M; net loss $208.2M ($1.52 per diluted share).
- FY2026 guidance: revenue $2.62-2.70B, gross margin ~63-65%, positive cash inflow.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604821/000110465926020482/0001104659-26-020482-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604821/000110465926020482/tm266979d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-020482

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer